Related Experiment Video
Updated: Apr 2, 2026
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
34.3K
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD:
Simon Thom1, Neil Poulter, Jane Field
1International Centre for Circulatory Health, Imperial College London, London, England. s.thom@imperial.ac.uk
JAMA
|September 5, 2013
Summary
Fixed-dose combination (FDC) therapy significantly improved medication adherence in cardiovascular disease (CVD) patients. This strategy also led to small but significant reductions in systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) levels.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Cardiovascular disease (CVD) management is challenged by poor long-term medication adherence.
- Fixed-dose combinations (FDCs) have shown promise in improving adherence in various clinical settings.
- Previous cardiovascular FDC trials primarily focused on short-term outcomes.
Purpose of the Study:
- To evaluate if an FDC strategy combining aspirin, a statin, and two blood pressure-lowering agents improves long-term adherence.
- To assess the impact of this FDC strategy on key CVD risk factors: systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C).
Main Methods:
- The UMPIRE trial was a randomized, open-label, blinded-endpoint study involving 2004 participants with established or at-risk CVD.
- Participants were assigned to either an FDC-based regimen or usual care.
- Adherence, SBP, and LDL-C changes were measured over a median follow-up of 15 months.
Main Results:
- The FDC group demonstrated significantly higher medication adherence (86% vs. 65%) compared to usual care.
- Concurrent statistically significant reductions in SBP (-2.6 mm Hg) and LDL-C (-4.2 mg/dL) were observed in the FDC group.
- Greater benefits in adherence and risk factor reduction were noted in patients with lower baseline adherence.
Conclusions:
- An FDC strategy for managing blood pressure, cholesterol, and platelet aggregation effectively improves medication adherence in CVD patients.
- This approach leads to statistically significant, albeit modest, improvements in SBP and LDL-C.
- The findings support the use of FDCs as a valuable tool in long-term CVD management.
More Related Videos
Related Concept Videos
01:01Dosage Regimen: Fixed Dose
2.5K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.5K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
548
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
548
01:28Dosage Regimens: Designs and Approaches
468
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
468
01:26Coronary Artery Disease IV: Preventive Measures
857
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
857
01:30Heart Failure V: Medical Management
544
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
544
01:26Atherosclerosis III: Management
583
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
583